Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, analyte specific reagents, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group B strep assays, ARIES group A strep assays, ARIES bordetella assays, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LMNX
Previous Symbol
CUSIP55027E10
Phone512-219-8020
Debt
Debt-to-Equity RatioN/A
Current Ratio6.60
Quick Ratio5.18
Price-To-Earnings
Trailing P/E Ratio43.56
Forward P/E Ratio46.57
P/E Growth3.13
Sales & Book Value
Annual Sales$306.57 million
Price / Sales3.93
Cash Flow$1.4104 per share
Price / Cash19.15
Book Value$10.50 per share
Price / Book2.57
Profitability
EPS (Most Recent Fiscal Year)$0.91
Net Income$29.42 million
Net Margins5.65%
Return on Equity5.99%
Return on Assets5.43%
Miscellaneous
Employees922
Outstanding Shares44,580,000
Market Cap$1.20 billion
OptionableOptionable
Luminex (NASDAQ:LMNX) Frequently Asked Questions
What is Luminex's stock symbol?
Luminex trades on the NASDAQ under the ticker symbol "LMNX."
How often does Luminex pay dividends? What is the dividend yield for Luminex?
Luminex announced a quarterly dividend on Wednesday, September 12th. Investors of record on Friday, September 21st will be given a dividend of $0.06 per share on Friday, October 12th. This represents a $0.24 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Thursday, September 20th. View Luminex's Dividend History.
How were Luminex's earnings last quarter?
Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings results on Monday, November, 5th. The medical instruments supplier reported $0.05 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.03. The medical instruments supplier earned $72.40 million during the quarter, compared to analyst estimates of $74.05 million. Luminex had a return on equity of 5.99% and a net margin of 5.65%. The company's revenue for the quarter was down 2.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.13 EPS. View Luminex's Earnings History.
When is Luminex's next earnings date?
What guidance has Luminex issued on next quarter's earnings?
Luminex issued an update on its FY 2018 earnings guidance on Monday, November, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $310-316 million, compared to the consensus revenue estimate of $313.62 million.Luminex also updated its Q4 2018 guidance to EPS.
What price target have analysts set for LMNX?
5 Wall Street analysts have issued 1 year price objectives for Luminex's stock. Their forecasts range from $22.00 to $33.00. On average, they expect Luminex's share price to reach $27.00 in the next year. This suggests that the stock has a possible downside of 0.0%. View Analyst Price Targets for Luminex.
What is the consensus analysts' recommendation for Luminex?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.
Has Luminex been receiving favorable news coverage?
Press coverage about LMNX stock has been trending somewhat positive on Sunday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Luminex earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Luminex's key competitors?
Some companies that are related to Luminex include Penumbra (PEN), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), AtriCure (ATRC), Nevro (NVRO), K2M Group (KTWO) and Orthofix Medical (OFIX).
Who are Luminex's key executives?
Luminex's management team includes the folowing people:
- Mr. Nachum Shamir, CEO, Pres & Director (Age 64)
- Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 56)
- Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 50)
- Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 48)
- Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 56)
Who are Luminex's major shareholders?
Luminex's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.89%), Renaissance Technologies LLC (4.41%), Dimensional Fund Advisors LP (4.35%), Acadian Asset Management LLC (3.67%), Neuberger Berman Group LLC (2.06%) and Glenmede Trust Co. NA (1.70%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.
Which institutional investors are selling Luminex stock?
LMNX stock was sold by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Panagora Asset Management Inc., Wells Fargo & Company MN, Martingale Asset Management L P, Dupont Capital Management Corp, GSA Capital Partners LLP, Renaissance Technologies LLC and Benjamin F. Edwards & Company Inc.. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II and Todd C Bennett. View Insider Buying and Selling for Luminex.
Which institutional investors are buying Luminex stock?
LMNX stock was acquired by a variety of institutional investors in the last quarter, including Glenmede Trust Co. NA, Bessemer Group Inc., PNC Financial Services Group Inc., Man Group plc, Russell Investments Group Ltd., Schroder Investment Management Group, AQR Capital Management LLC and Assenagon Asset Management S.A.. View Insider Buying and Selling for Luminex.
How do I buy shares of Luminex?
Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Luminex's stock price today?
One share of LMNX stock can currently be purchased for approximately $27.01.
How big of a company is Luminex?
Luminex has a market capitalization of $1.20 billion and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe.
What is Luminex's official website?
How can I contact Luminex?
Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]
MarketBeat Community Rating for Luminex (NASDAQ LMNX)
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
